European Primary Care Cardiovascular Society

Prescription rates of GLP-1RA and SGLT2i in patients with T2D and CVD

News - Oct. 9, 2023

Real-life use of novel glucose lowering agents in coronary artery disease

Presented at the EASD 2023 by: Pia Lundman, MD, PhD - Stockholm, Sweden

Introduction and methods

Several RCTs have confirmed the preventive cardiovascular effects of SGLT2i and GLP-1RA in patients with T2D and CVD. The current study investigated the prescription pattern of novel glucose lowering drugs (defined in the study as SGLT2i and GLP-1RA) in patients with T2D and CAD in the national wide SWEDEHEART-registry.

A total of 38,671 patients from Sweden were included from 2010 to 2021 in the analysis. All patients had T2D and were admitted for coronary angiography (71% with acute MI, 29% with stable CAD). Information Mortality was followed until December 2021.

Main results


Results of this real-life study showed a rapid increase in the use of SGLT2i and GLP1-RA in patients with T2D and CAD in Sweden. “This is an encouraging adaption towards guideline directed medical therapies, where however the use of GLP-1RA is lower than the use of SGLT2i”, said Pia Lundman.

- Our reporting is based on the information provided at the EASD 2023 -

Share this page with your colleagues and friends: